OCRA is now on Shopify and Poshmark Wardrobe need a refresh? Now you can shop high-end, limited quantity designer goods online at deep discounts, all while supporting the fight against ovarian cancer. Browse our exciting collection of shoes, accessories, and apparel for women, men and children, from top brands including Johnny Was, Ramy Brook, Kenneth … Continued
(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers. The guidelines, a summary of which can be found here, have been updated after several studies were completed and the FDA approved several new drugs. The new guidelines address topics such as PARP … Continued
(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers. Phase 1 trials are used … Continued
(March 20, 2019) Earlier this month, OCRA united advocates from across the country for Spring Advocacy Day on Capitol Hill. Together, this passionate group of survivors, caregivers and supporters used their collective voice to advocate for increased funding for ovarian cancer research and education. Learn more about our asks for Ovarian Cancer Research Program (OCRP) … Continued
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! Tell Congress to Increase OCRP Funding The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a … Continued
(March 18, 2019) Before the most recent study on the usage of lymphadenectomy, published earlier this month in the New England Journal of Medicine, it was thought that surgically removing clinically negative lymph nodes had a positive effect on the patient’s health. Now, doctors are rethinking that approach. The LION, Lymphadenectomy in Ovarian Neoplasms, trial … Continued
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued
(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued
(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women … Continued
(February 28, 2019) Toni Harris, 22, is shaking up the world of college football, and making history as the first female to earn a scholarship to play at a 4-year university. And she’s not only paving the way for future generations of women to follow their dreams in the sport – she’s also inspiring ovarian … Continued
Curious about the status of ovarian cancer research and treatments? Want to meet other survivors? You need to attend OCRA’s Ovarian Cancer National Conference. July 12-14, 2019Seattle, WAHyatt Regency Seattle Early Bird Registration is now open! OCRA’s Ovarian Cancer National Conference® is the largest, most trusted conference for ovarian cancer survivors, caregivers, supporters and experts. … Continued
(February 26, 2019) Ovarian Cancer Research Alliance is pleased to announce Beth Y. Karlan, M.D as our new chair of OCRA’s Scientific Advisory Committee. Our Scientific Advisory Committee is comprised of 24 illustrious and respected leaders in research on treating women with ovarian cancer. Dr. Karlan is Professor and Vice Chair of Women’s Health Research … Continued
Get email updates about research news, action alerts, and ways to join the fight.
